Salgkamis, Dimitrios
Sifakis, Emmanouil G.
Agartz, Susanne
Wirta, Valtteri
Hartman, Johan
Bergh, Jonas
Foukakis, Theodoros
Matikas, Alexios
Zerdes, Ioannis
Funding for this research was provided by:
Region Stockholm
Karolinska Institutet
Cancer Research KI
Swedish Cancer Society
Radiumhemmet
Karolinska Institute
Article History
Received: 30 January 2024
Accepted: 2 August 2024
First Online: 6 August 2024
Competing interests
: Alexios Matikas: consultancy or speaker (no personal fees): Roche, Veracyte, Seagen. Research funding paid to institution: AstraZeneca, Merck, Novartis; Valtteri Wirta: speaker’s honoraria and reimbursement of travel expenses from Illumina; Johan Hartman: speaker’s honoraria or advisory board remunerations from Roche, Novartis, Pfizer, EliLilly, MSD and institutional research support from Roche, AstraZeneca and Novartis. Co-founder and shareholder of Stratipath AB; Jonas Bergh: Research grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche and Sanofi-Aventis to Karolinska Institutet and/or University Hospital. No personal payments. Co-author on a chapter on “Prognostic and Predictive factors in early, non-metastatic breast cancer” in UpToDate. Honoraria to Asklepios Medicin HB. Stocks in Stratipath AB, a company involved in Al-based diagnostics for breast cancer. Chairperson for Coronis and Asklepios Cancer Research HB. Honoraria from Roche and AstraZeneca for chairmanship and lectures at scientific meetings and consultations for Stratipath AB; Theodoros Foukakis: Financial Interests, Institutional, Invited Speaker: Roche, AstraZeneca, Gilead Sciences. Financial Interests, Personal, Advisory Board: Novartis, Veracyte, Exact Sciences, Affibody. Financial Interests, Personal, Invited Speaker: Pfizer. Financial Interests, Personal, Royalties, Authorship of two chapters in UpToDate: Wolters Kluwer. Financial Interests, Institutional, Coordinating PI, Clinical trial support (research grant and study drug): Pfizer. Financial Interests, Institutional, Sponsor and Coordinating PI, International co-PI of academic trial ARIADNE (EU CT: 2022-501504-95-00): AstraZeneca, Novartis, Veracyte; All other authors have no conflicts of interest to disclose.